[Asia Economy Reporter Lee Gwan-joo] Hanmi Pharmaceutical's neutropenia treatment 'Rolontis' (U.S. name Rolbedon), approved by the U.S. Food and Drug Administration (FDA), has gained momentum in targeting the local market as it has been included in the treatment guidelines of 32 cancer centers in the United States.
Hanmi Pharmaceutical's U.S. partner, Spectrum, announced on the 7th that Rolbedon has been included in the febrile neutropenia prevention and treatment option guidelines presented by the National Comprehensive Cancer Network (NCCN) in the U.S.
NCCN is a nonprofit alliance formed by 32 leading cancer centers in the United States for cancer patient treatment, research, and education. The guidelines presented by NCCN are recognized as the standard for cancer treatment policies and clinical directions. They are also the most trusted clinical practice guidelines used across all medical fields.
The NCCN guidelines recommend appropriate use of growth factors in the clinical management of febrile neutropenia and included Rolbedon as a treatment option for neutropenia management.
Tom Lee, president of Spectrum, said, "The NCCN guidelines are the standard guidelines for determining the best treatment for cancer patients, and we are pleased that Rolbedon was quickly included in these guidelines. The inclusion in the guidelines has strengthened Rolbedon's clinical profile, marking an important milestone for the Rolbedon program."
Rolbedon is a biopharmaceutical used for the treatment or prevention of severe neutropenia occurring in cancer patients who have undergone chemotherapy. It applies Hanmi Pharmaceutical's proprietary platform technology 'Lapscovery,' which dramatically enhances the efficacy of biopharmaceuticals. It is the sixth domestic new drug to obtain FDA approval and the first new drug produced in Korea and sold in the U.S. market.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
